# Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

> **NCT01849939** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 43 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Lymphocytic Lymphoma

## Interventions

- **DRUG:** Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)

## Key facts

- **NCT ID:** NCT01849939
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2013-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849939, "Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT01849939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*